Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00605423 | The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot | PHASE2 | COMPLETED | 6 | — | — | Jan 1, 2008 | Nov 1, 2011 | Apr 7, 2014 | 1 | United States |
Visual acuity is measured using ETDRS charts at 4 meters.
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Dose 0.2 ug/day Medidur implant |
| 2 | ACTIVE_COMPARATOR | Dose 0.5 ug/day Medidur implant |
| Name | Type | Description |
|---|---|---|
| Fluocinolone Acetonide/Medidur | DRUG | 0.2 ug/day implant |
Inclusion Criteria: * Patients 50 or greater * Treated with intraocular injections of Lucentis for at least 6 months and have reached a plateau, defined as 2 consecutive visits (4-6 weeks apart) with no improvement in VA (worse or within one line better) or center subfield thickening (worse or with...